Phase II trial of taxol in patients with metastatic renal cell carcinoma.
Based on results of previous Phase I studies, 18 patients with documented metastatic renal cell carcinoma received Taxol 250 mg/m2 as a 24-h infusion, repeated every 21 days in this Phase II study. All patients received premedication with dexamethasone, diphenhydramine, and cimetidine. There were no responses in the 18 patients treated.
Einzig
A I
AI
Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York.
Gorowski
E
E
Sasloff
J
J
Wiernik
P H
PH
D000328:Adult; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel
D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel